Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4261 AL 4275

Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Sepehry AA, Sarai M, Hsiung GR.

Can J Neurol Sci. 2017 May;44(3):267-275. doi: 10.1017/cjn.2016.426. Epub 2017 Feb 2.

Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial

Jia J, Wei C, Jia L, Tang Y, Liang J, Zhou A, Li F, Shi L, Doody RS.

J Alzheimers Dis. 2017;56(4):1495-1504. doi: 10.3233/JAD-161117.

Nanotechnology for Alzheimer Disease

Leszek J, Md Ashraf G, Tse WH, Zhang J, Gasiorowski K, Avila-Rodriguez MF, Tarasov VV, Barreto GE, Klochkov SG, Bachurin SO, Aliev G.

Curr Alzheimer Res. 2017;14(11):1182-1189. doi: 10.2174/1567205014666170203125008.

Galantamine Response Associates with Agitation and the Prefrontal Cortex in Patients with Alzheimer's Disease

Nakayama S, Suda A, Nakanishi A, Motoi Y, Hattori N.

J Alzheimers Dis. 2017;57(1):267-273. doi: 10.3233/JAD-160902.

Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities

Theleritis C, Siarkos K, Katirtzoglou E, Politis A.

J Geriatr Psychiatry Neurol. 2017 Jan;30(1):26-49. doi: 10.1177/0891988716678684.

Low Florbetapir PET Uptake and Normal Aβ1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier

Lombardi G, Berti V, Tedde A, Bagnoli S, Piaceri I, Polito C, Lucidi G, Ferrari C, Ginestroni A, Moretti M, Pupi A, Nacmias B, Sorbi S.

J Alzheimers Dis. 2017;57(3):697-703. doi: 10.3233/JAD-161170.

Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease

Reeves S, McLachlan E, Bertrand J, D'Antonio F, Brownings S, Nair A, Greaves S, Smith A, Taylor D, Dunn J, Marsden P, Kessler R, Howard R.

Brain. 2017 Apr 1;140(4):1117-1127. doi: 10.1093/brain/aww359.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, Chen S, Devous MD Sr, Seibyl J, Marek K, Siemers ER, Mintun MA.

Alzheimers Dement. 2017 Oct;13(10):1117-1124. doi: 10.1016/j.jalz.2017.02.009. Epub 2017 Mar 30.

Alzheimer Disease: Monotherapy vs. Combination Therapy

Lawler E, Avila A.

Am Fam Physician. 2017 Apr 1;95(7):452.

Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial

Xiao S, Wang T, Ma X, Qin Y, Li X, Zhao Z, Liu X, Wang X, Xie H, Jiang Q, Sun L, Luo B, Shang L, Chen W, Bai Y, Tang M, He M, Wu L, Ma Q, Hou D, He J.

Age Ageing. 2017 Sep 1;46(5):767-773. doi: 10.1093/ageing/afx045.

Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease

Hsu CW, Lee Y, Lee CY, Lin PY.

Clin Neuropharmacol. 2017 May/Jun;40(3):147-148. doi: 10.1097/WNF.0000000000000215.

Remyelination: A Potential Therapeutic Strategy for Alzheimer's Disease?

Sun J, Zhou H, Bai F, Zhang Z, Ren Q.

J Alzheimers Dis. 2017;58(3):597-612. doi: 10.3233/JAD-170036.

Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

Ahmad J, Akhter S, Rizwanullah M, Khan MA, Pigeon L, Addo RT, Greig NH, Midoux P, Pichon C, Kamal MA.

Curr Alzheimer Res. 2017;14(11):1164-1181. doi: 10.2174/1567205014666170508121031.

Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis

Orgeta V, Tabet N, Nilforooshan R, Howard R.

J Alzheimers Dis. 2017;58(3):725-733. doi: 10.3233/JAD-161247.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias